Rho GDP dissociation inhibitor α silencing attenuates silicosis by inhibiting RhoA/Rho kinase signalling.


Journal

Experimental cell research
ISSN: 1090-2422
Titre abrégé: Exp Cell Res
Pays: United States
ID NLM: 0373226

Informations de publication

Date de publication:
15 07 2019
Historique:
received: 13 03 2019
revised: 21 04 2019
accepted: 23 04 2019
pubmed: 29 4 2019
medline: 1 7 2020
entrez: 29 4 2019
Statut: ppublish

Résumé

Transforming growth factor-β1 (TGF-β1) alters the fibroblast phenotype by promoting transdifferentiation into myofibroblasts, which exhibit the ability to promote collagen synthesis and extracellular matrix (ECM) deposition, thereby playing a significant role in the pathology of silicosis. In this study, we investigated the regulatory mechanisms involved in myofibroblast transdifferentiation. Two-dimensional gel electrophoresis showed that Rho GDP-dissociation inhibitor α (RhoGDIα) was upregulated following myofibroblast transdifferentiation stimulated by TGF-β1. We hypothesised that RhoGDIα may induce myofibroblast transdifferentiation and thus result in silicosis. Accordingly, the biological significance of RhoGDIα in cell proliferation and apoptosis was investigated by deletion of RhoGDIα in MRC-5 cells. In addition, a mechanistic study showed that fasudil, an inhibitor of the RhoA/Rho kinase (ROCK) signalling pathway, reduced the levels of RhoGDIα, RhoA, and phospho-myosin phosphatase (phospho-MYPT) in MRC-5 cells and silicosis model rats. Knockdown of RhoGDIα inhibited myofibroblast transdifferentiation and collagen deposition through RhoGDIα/RhoA/ROCK signalling in silicosis model mice. Overall, downregulation of RhoGDIα may significantly promote cell apoptosis and inhibit cell growth, resulting in reversal of myofibroblast transdifferentiation by RhoA/ROCK in vitro and in vivo. These data will facilitate further exploration of the potential use of RhoGDIα as a target for silicosis therapy.

Identifiants

pubmed: 31029634
pii: S0014-4827(19)30210-1
doi: 10.1016/j.yexcr.2019.04.026
pii:
doi:

Substances chimiques

rho Guanine Nucleotide Dissociation Inhibitor alpha 0
RHOA protein, human 124671-05-2
rho-Associated Kinases EC 2.7.11.1
rhoA GTP-Binding Protein EC 3.6.5.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

131-140

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Zhongqiu Wei (Z)

Basic Medical College, Hebei Medical University, Shijiazhuang, China.

Hong Xu (H)

Medical Research Center, Hebei Key Laboratory for Organ Fibrosis, North China University of Science and Technology, Tangshan, China.

Yi Zhang (Y)

Medical Research Center, Hebei Key Laboratory for Organ Fibrosis, North China University of Science and Technology, Tangshan, China.

Xue Yi (X)

Key Laboratory of Functional and Clinical Translational Medicine, Fujian Province University, Department of Basic Medicine, Xiamen Medical College, Xiamen, China.

Xinyu Yang (X)

Medical Research Center, Hebei Key Laboratory for Organ Fibrosis, North China University of Science and Technology, Tangshan, China.

Yingying Chen (Y)

Medical Research Center, Hebei Key Laboratory for Organ Fibrosis, North China University of Science and Technology, Tangshan, China.

Na Mao (N)

Medical Research Center, Hebei Key Laboratory for Organ Fibrosis, North China University of Science and Technology, Tangshan, China.

Shifeng Li (S)

Basic Medical College, Hebei Medical University, Shijiazhuang, China.

Dingjie Xu (D)

College of Traditional Chinese Medicine, North China University of Science and Technology, Tangshan, China.

Shumin Li (S)

Basic Medicine College, North China University of Science and Technology, Tangshan, China.

Hui Zhang (H)

Medical Research Center, Hebei Key Laboratory for Organ Fibrosis, North China University of Science and Technology, Tangshan, China.

Dan Li (D)

Medical Research Center, Hebei Key Laboratory for Organ Fibrosis, North China University of Science and Technology, Tangshan, China.

Guizhen Zhang (G)

Medical Research Center, Hebei Key Laboratory for Organ Fibrosis, North China University of Science and Technology, Tangshan, China.

Bonan Zhang (B)

Basic Medicine College, North China University of Science and Technology, Tangshan, China.

Fuyu Jin (F)

Medical Research Center, Hebei Key Laboratory for Organ Fibrosis, North China University of Science and Technology, Tangshan, China.

Xuemin Gao (X)

Basic Medical College, Hebei Medical University, Shijiazhuang, China.

Wenchen Cai (W)

College of Preventive Medicine, North China University of Science and Technology, Tangshan, China.

Lijuan Zhang (L)

Medical Research Center, Hebei Key Laboratory for Organ Fibrosis, North China University of Science and Technology, Tangshan, China.

Ruimin Wang (R)

Medical Research Center, Hebei Key Laboratory for Organ Fibrosis, North China University of Science and Technology, Tangshan, China.

Fang Yang (F)

Basic Medical College, Hebei Medical University, Shijiazhuang, China. Electronic address: fangyang@ncst.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH